Braftovi Combo Delays Progression in BRAF-Mutant mCRC

A targeted treatment that includes Braftovi (encorafenib) plus Erbitux (cetuximab) and chemotherapy helped patients with a specific form of metastatic colorectal cancer live longer without their disease getting worse, according to new results from cohort 3 of the phase 3 BREAKWATER clinical trial.

The study focused on people whose tumors carry the BRAF V600E mutation, a genetic change linked to more aggressive disease and fewer effective first-line treatment options. Patients who received the Braftovi-based regimen experienced a statistically significant and clinically meaningful improvement in progression-free survival, meaning their cancer stayed under control longer than those who received standard chemotherapy with or without Avastin (bevacizumab).

Overall survival results also showed a meaningful improvement trend. The news release in which these data were shared also reported that the safety profile of the combination was consistent with what is already known about each medicine, and no new safety concerns were identified.

“These results build on the positive objective response rate data we recently shared, providing further evidence of the meaningful benefit this BRAFTOVI-based targeted approach may offer patients with BRAF V600E-mutant metastatic colorectal cancer,” Jeff Legos, CEO of Pfizer, said in the news release. “The combination of significant responses and now improvement in progression‑free survival underscores the potential of BRAFTOVI as a potentially practice-changing treatment option for patients and families facing this challenging diagnosis.”

What the BREAKWATER results mean for patients with BRAF V600E metastatic colorectal cancer

For people newly diagnosed with metastatic colorectal cancer that carries a BRAF V600E mutation, treatment options have historically been limited and outcomes poorer than for many other patients. The BREAKWATER findings suggest that starting therapy with a biomarker-driven, targeted approach may help control the disease longer than standard chemotherapy alone.

Earlier data from the same trial already showed that more patients had tumor shrinkage with the Braftovi combination. The new analysis adds another important measure: patients went longer before their cancer progressed.

If approved for this setting, this regimen could become a cornerstone first-line treatment for this subgroup of patients. Currently, Braftovi is approved in combination with Erbitux and mFOLFOX6 under accelerated approval for previously untreated BRAF V600E metastatic colorectal cancer, based on tumor response rates. Continued approval depends on confirming long-term clinical benefit.

Understanding BRAF V600E Mutations in Colorectal Cancer

Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related death. Approximately 20% of patients are diagnosed after the disease has already spread, and up to half of those diagnosed earlier will eventually develop metastatic disease.

BRAF mutations occur in approximately 8% to 12% of metastatic colorectal cancers. The V600E mutation is the most common and is associated with a poorer prognosis, including shorter survival and reduced response to traditional chemotherapy.

Targeted therapies such as Braftovi are designed to block the abnormal BRAF protein, which is part of the MAPK signaling pathway that helps cancer cells grow and survive. By combining a BRAF inhibitor with Erbitux, which targets EGFR, researchers aim to shut down multiple growth signals at the same time. Adding chemotherapy may further enhance cancer control.

How the BREAKWATER Trial Was Designed

BREAKWATER is a global phase 3, randomized, multicenter study evaluating Braftovi with Erbitux, either alone or with chemotherapy, compared with standard chemotherapy regimens.

The new results come from cohort 3, which enrolled patients who had not received prior treatment for metastatic disease. Participants were randomly assigned to receive with Braftovi plus Erbitux and FOLFIRI, or FOLFIRI with or without Avastin.

The primary goal of this cohort was to measure objective response rate, meaning how many patients had meaningful tumor shrinkage. Progression-free survival was a key secondary end point and was assessed by an independent central review to reduce bias.

Patients in cohort 3 had previously untreated metastatic colorectal cancer with a confirmed BRAF V600E mutation. All participants were considered appropriate candidates for combination chemotherapy.

This group reflects a real-world population of patients who often face more aggressive disease biology and limited first-line targeted treatment options.

Additional Findings and What Comes Next

At the time of the analysis, the Braftovi combination continued to show a manageable safety profile. Common side effects were consistent with those expected from chemotherapy, Erbitux and BRAF-targeted therapy, including fatigue, nausea, rash and low blood counts.

Researchers plan to present full data at an upcoming medical meeting and submit the results to the U.S. Food and Drug Administration to support potential expanded approval of the Braftovi, Erbitux and FOLFIRI regimen.

For patients, these findings highlight the growing importance of biomarker testing in colorectal cancer. Identifying a BRAF V600E mutation can help guide treatment decisions and may open the door to targeted therapies that offer longer disease control.

Although more follow-up is needed to confirm long-term survival benefits, the BREAKWATER results may represent a step toward more personalized first-line treatment for this high-risk subgroup of metastatic colorectal cancer.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI and reviewed by a human editor.

References

1. “Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer,”by Pfizer Inc. News release; Feb. 17, 2026.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.